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ABSTRACT It is well established that integrin 41 binds to the vascular cell adhesion molecule (VCAM) and fibronectin and
plays an important role in signal transduction. Blocking the binding of VCAM to 41 is thought to be a way of controlling a
number of disease processes. To better understand how various inhibitors might block the interaction of VCAM and
fibronectin with 41, we began constructing a structure model for the integrin 41 complex. As the first step, we have built
a homology model of the 1 subunit based on the I domain of the integrin CD11B subunit. The model, including a bound Mg2
ion, was optimized through a specially designed relaxation scheme involving restrained minimization and dynamics steps. The
native ligand VCAM and two highly active small molecules (TBC772 and TBC3486) shown to inhibit binding of CS-1 and
VCAM to 41 were docked into the active site of the refined model. Results from the binding analysis fit well with a
pharmacophore model that was independently derived from active analog studies. A critical examination of residues in the
binding site and analysis of docked ligands that are both potent and selective led to the proposal of a mechanism for 1/7
ligand binding selectivity.
INTRODUCTION
Integrins are cell-adhesion molecules expressed on the sur-
face of cells, and they are involved in cell–cell and cell–
matrix interactions (Adams and Lobb, 1999; Horwitz,
1997). Each integrin is a heterodimer composed of one 
and one  subunit, and 20  pairs have been discovered
(Chothia and Jones, 1997; Haas and Plow, 1994). The
integrin very-late antigen-4 (VLA-4) is one of two known
4 integrins, and it is the counter-receptor for the vascular
cell adhesion molecule (VCAM-1) and the CS-1 splice
variant of fibronectin (Elices et al., 1990; Wayner et al.,
1989). Binding of VCAM-1 to 41 is important in the
inflammatory response, and blocking this interaction would
be expected to be important in controlling many diseases
(Irie et al., 1995). Understanding the nature of the interac-
tion between the integrin and cell adhesion molecules can
aid in the design of potent therapeutics. It has been shown
that small cyclic peptides based on segments from either
CS-1 or VCAM-1 can inhibit the VCAM-1–integrin inter-
action (Vanderslice et al., 1997; Wang et al., 1995), and
these peptides were used to design very potent small mo-
lecular therapeutics (Adams and Lobb, 1999; Jackson et al.,
1997; Kc et al., 1999). Antibody binding studies and mu-
tagenesis data also point to the involvement of both the 
(Schiffer et al., 1995; Loftus et al., 1994; Kamata et al.,
1995; Irie et al., 1995) and  (Kamata et al., 1995; Puzon-
McLaughlin and Takada, 1996) subunits in binding. How-
ever, the detailed mechanism of ligand–receptor interac-
tions remains unclear due to the lack of a three-dimensional
(3D) structure of the 41 complex.
In some integrin  subunits, there is a special residue
sequence referred to as the I domain, and there is growing
evidence for its importance in ligand binding (Loftus et al.,
1994; Lee et al., 1995a). The I domain is a sequence of
190 residues near the N terminus of the  subunit that is
homologous to the A domains of von Willebrand factor
(VWFA) (Lee et al., 1995a). The I domains known to date
adopt a dinucleotide-binding fold and contain a metal ion-
dependent adhesion (MIDAS) motif with a bound dication
(usually Mg2) at the top of the  sheet (Lee et al., 1995b;
Emsley et al., 1997). A number of groups have proposed
that a topology similar to the I domain is present within the
integrin  subunit (Puzon-McLaughlin and Takada, 1996;
Tuckwell and Humphries, 1997). Based on detailed second-
ary structural comparisons, Tuckwell and Humphries con-
cluded that the ligand-binding region of integrin  subunits
is homologous to the N terminal region of the VWFA
domain. Here, we describe the work of constructing a 1
homology model based on the I domain of integrin CD11B/
CD18 with bound Mg2 (PDB entry 1ido) (Lee et al.,
1995b). This was the first step of our effort to build a
complete 41 complex structure model aimed at exploring
the landscape of the interactions between the cell adhesion
molecules and their inhibitors. The refined 1 homology
model was used to study the binding mechanism of some de
novo synthesized compounds and to verify a pharmacoph-
ore model previously derived from active analog analysis
(Holland, 1999). Based on the ligand binding study, a pos-
sible mechanism behind ligand selectivity between 41
and 47 is proposed.
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MATERIALS AND METHODS
General
The Homology and Discover modules (Biosym/MSI, 1995) of the Insight®
II molecular modeling system were used in the construction and optimi-
zation of the 1 structure. The CVFF force field was used for all energy
calculations, and nonbonded interactions were handled fully without using
a cutoff. A distance-dependent dielectric constant of 4r was applied to all
nonbonded interactions to simulate an aqueous environment. The sequence
for 1 was obtained from National Center for Biotechnology Information
(Wheeler et al., 2000) as the PIR accession number B27079 (Barker et al.,
2000). Only a portion of 1 sequence from residues 121 to 311, which
matches the length of the template protein, was used in this study.
Template selection
Because it is widely argued that 1 may share many biological features of
the I domain that exists in a number of integrin  subunits (Puzon-
McLaughlin and Takada, 1996; Tuckwell and Humphries, 1997), we used
this as a primary guide for the selection of a template for 1. A detailed
examination of the two-dimensional (2D) structural features of the I
domains from a number of integrin  subunits whose crystallographic data
are available indicated that the structure-conserved regions (SCRs) of the
I domain are composed mainly of alternating -helical and -strand motifs.
We then compared the consensus 1 secondary composition (2D motifs
and their distribution) predicted by various protein secondary structure
prediction programs (Deleage et al., 1997) with those present in CD11A/
CD11B, two integrin I domains with the highest resolution crystal struc-
tures. Closely resembled secondary composition patterns were easily iden-
tified, as shown in Fig. 1. Therefore, we have chosen CD11A/CD11B as
our template proteins. To validate our approach based on consensus 2D
structure prediction, we also applied the same programs to CD11A/CD11B
and compared the consensus-predicted 2D structures with those presented
in their crystal structure. An extremely high fit can be identified for each
of them. To confirm the choice of I domain as a suitable template for 1,
we also conducted a series of protein fold recognition studies using various
programs such as GENEFOLD (Sybyl, 1999). Results from these studies
also strongly supported our template selection, because all programs gave
a rather high preference for CD11A/CD11B.
Sequence alignment
Three steps were taken to achieve a highly optimized sequence alignment
for 1. First, the consensus 2D structure pattern of 1 was compared to
those of CD11A and CD11B, and adjustments were made to maximize the
match of the corresponding 2D motifs, as shown in Fig. 2. Mapping of 2D
elements ensures the inheritance of SCRs from the template protein.
Second, for variable regions in the 1 sequence sharing low homology with
FIGURE 1 Results of secondary structure predictions on the 1, CD11A(1lfa), and CD11B(1ido) sequences. E, H, and C are character codes for residues
predicted in  strand,  helix, and coil regions, respectively. The consensus-predicted  and  motifs are represented by a and b, respectively, followed
by a number representing the count of that motif type. The motifs with a  attached indicate that they occur in only one of the template proteins.
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the template, a BLAST (Altschul et al., 1997) search was carried out to
search for protein fragments with a higher sequence homology. If such
fragments were found and a consensus configuration could be derived from
them, then these fragments were used as a local template for that region.
Third, final adjustments were made to align important residues, such as
those in the binding site and those involved in disulfide linkages. At the
same time, careful attention was paid to minimize inserted gaps and
maximize the overall sequence homology.
Initial model generation
After the sequence alignment, two steps were taken to build an initial 3D
model of 1 subunit. First, the backbone coordinates of the SCRs were
copied from the template protein, and each side chain in the template was
replaced by that of the corresponding target residue by aligning the C–C
bonds. This is a standard procedure in most homology modeling packages.
Second, the coordinates of the residues in variable regions were copied
from peptide fragments generated by one of the following methods: a local
template fragment if found, protein databank screening, and de novo
generation. The last two methods are provided through the Homology
module of Insight II package from MSI (Biosym/MSI, 1995). In the
databank screening method, a search is done for real protein fragments
fitting the distance specified by the two ending points. It usually suffers
from a low hit rate, possibly a distorted junction geometry and ignorance
of sequence homology when selecting fragments. De novo generation
provides a universal method for generating loops and it can be used when
other methods fail. However, it does give artificial peptide geometry that is
difficult to correct in later stages of structure refinement. Actually, our
approach of selecting a local template is an improvement to the database
screening method that takes into account sequence homology when select-
FIGURE 2 Alignment of CD11A, CD11B, and 1 sequences. Also listed are other protein sequences providing local templates. The sequence boxes
cover the regions in which the backbone of a template is copied into the target protein. The notation for each PDB entry is given as follows: 1amk.pdb,
Leishmania Mexicana triose phosphate isomer; 1mda.pdb Chain J, methylamine dehydrogenase (E.C.1.4.99.3) with amicyanin; 1oac.pdb, copper amine
oxidase; 1aor.pdb, aldehyde ferredoxin oxidoreductase protein complexed with molybdopterin.
1 Homology Model and Ligand Binding Analysis 449
Biophysical Journal 82(1) 447–457
ing fragments. In our approach, the fragment representing the consensus
configuration found via a BLAST search was carefully spliced with the
template structure to best bridge the gap. To accomplish this splicing, the
loop fragment was manually aligned with the ends of the template and both
parts were extended or contracted one residue at a time until an acceptable
junction geometry was obtained. To build the variable loop regions, we
first applied our local template approach, and coordinates were generated
whenever high homologous fragments could be identified. Coordinates for
the variable regions where the local templates could not be selected were
assigned from either a protein databank screen or de novo generation if the
prior two methods failed. Avoiding conflicts with other sections of the
protein and fitting the overall template topology were primary criteria for
determining a loop orientation for each variable region.
Structure refinement
A consequence of copying template coordinates in homology modeling is
that the initial 3D structure inevitably contains serious conflicts among side
chains of the constructed protein. This is due to changes in size and charge
state. We designed a specific optimization protocol aimed at fully relaxing
our initial model while preserving its inherited topological features. The
refinement was accomplished in multiple steps involving restrained energy
minimization and molecular dynamics. Once all atomic coordinates were
assigned, the structure was initially refined by repairing junction distortions
between loops and SCRs. It involved the minimization of residues span-
ning the two sides of a junction, and was accomplished with the tools
available in the Insight II homology model (Biosym/MSI, 1995). Complet-
ing this step helps to correct the peptide bond length and torsion in the
junctions and smooth out junction orientations. After this step, the site for
placing Mg2 was identified by overlapping the model and CD11B binding
sites and copying the coordinates of Mg2 from the template. Because all
of metal coordinating residues in CD11A were matched to those in our
sequence alignment, a reasonable assumption was made that the 1 model
should share a similar metal coordination pattern with the template. To
preserve the metal coordinating features, distance restraints were placed on
all coordinating atom pairs during the following refinement steps. Because
all MgO distances in the template metal coordination are between 2.00
and 2.25 Å, we used these two values as lower and upper boundaries of the
distance restraints. In addition, the backbone atoms of all SCR residues
were fixed during the initial stages of refinement process to prevent SCR
from deforming significantly. First, a multiple-step steepest-decent (SD)
minimization was conducted to correct most severe stereo conflicts and
prepare the model for further relaxation. Then, a dynamics simulation was
performed at 298 K to further release the stereo conflicts that survived from
previous simple minimization protocol. At this point, the fixed atoms in
SCRs hindered further relaxation, so the constraints on fixed backbone
atoms in SCRs were replaced by tether restraints of 1000 kcal/(molÅ2)
during the next multiple-step conjugate-gradient (CG) minimization pro-
cess. The use of tether restraint was to preserve the overall geometric
features of SCR regions. Last, a combined dynamics and minimization
process with relaxed metal coordinating restraints was used to fine-tune the
final structure model.
Ligand binding analysis
The native ligand VCAM and several synthetic compounds were used to
study their possible binding modes to 1 and 41 complex. First, for each
ligand molecule whose conformation was undetermined, a thorough search
using molecular dynamics of at least 100 ps was carried out, and the most
energetically favorable conformation best fitting the pharmacophore model
derived previously from active analog analysis (Holland, 1999) was chosen
as its bioactive conformation. Second, each ligand molecule was manually
introduced into the 1 active site to maximize the favorable interactions
specified by the pharmacophore model. If such a favorable docking pattern
could be identified, the system then underwent a further refinement pro-
tocol to determine the final binding mode. The protocol started with an
initial minimization process of ligand with entire 1 fixed to adjust their
relative orientation and correct any steric collision caused by manual
docking. Next, a limited dynamics and minimization protocol was carried
out on both ligand and 1 atoms in the active site (defined as residues
within a spherical range of 12 Å from the metal ion) while keeping the rest
of acceptor fixed. The last step of the refinement is necessary, because it
allows both ligand and target to relax while searching for the relative
orientation that optimizes the interactions between them.
RESULTS AND DISCUSSION
Sequence alignment
Because the overall sequence homology between 1 and the
template proteins CD11A/CD11B is 33.5%, we first fo-
cused on the alignment of the secondary structure motifs
between them to ensure the preservation of SCRs. However,
the sequence homology increases significantly (from 33.5%
to 45.6%) as the local templates are applied to the sequence
alignment as shown in Fig. 2. There were two helical
regions present in both template proteins yet absent from
predicted 1 secondary motifs. In one of these regions, the
sequence fragment corresponding to two short helices, a2
and a3, in CD11A and CD11B was predicted as a random
coil by all secondary structure prediction programs (See Fig.
1). Application of a BLAST search based on the local
sequence in this region resulted in two highly homologous
protein fragments, both of which were in coiled configura-
tions. In the other region, the consensus secondary predic-
tion indicated a  strand in a sequence segment where a
helix (a6) was present in both CD11A and CD11B. Again,
the BLAST search led us to a highly homologous protein
fragment (5/10 identity, 9/10 similarity) in a  strand motif.
Because both of these discrepancies in secondary motifs
occurred in the surface regions of the template, it could be
argued that helices in the template were less conserved than
the  strands, which formed the topological core of I do-
main structure. Therefore, they might be more vulnerable to
evolutionary mutations. This argument is further supported
by the observation that the helical compositions in CD11A
and CD11B were somewhat different, whereas those of 
strands were rather consistent. For example, three short
helices in CD11A (a4, a5, and a6) were not present in
CD11B. All of these arguments render ample support for
using the protein fragments as local templates for these
regions.
By our alignment, all Mg2 coordinating residues in
CD11B were aligned to the identical ones in 1 model,
namely, D130, S132, S134, T206, and D226. Because most
of these active site residues were determined by mutagen-
esis experiments as critical residues in ligand binding, (Pu-
zon-McLaughlin and Takada, 1996) the residual identity
inherited by our alignment would ensure the preservation of
metal coordinating pattern of the template protein. Further-
more, our sequence alignment also easily accommodates
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four cysteine residues that are absent from the template
protein. Two of them are sequentially close to each other
and sit in a single loop, whereas the other pair, though
distant in sequence, is close enough in space to form a
disulfide linkage.
Model evaluation
The structures of refined model were evaluated with the
PROCHECK V3.0 (Laskowski et al., 1993). PROCHECK
analyzes the backbone ,  torsion angles of a protein and
uses the percentage occupancies for “core,” “allowed,”
“generously allowed,” and “disallowed” regions as the qual-
ity measurement of a protein structure. For a fair assessment
of our 1 model, we also conducted PROCHECK calcula-
tions on 176 out of 192 theoretical models (16 structures
would not score properly as submitted to PROCHECK)
available from the PDB databank. The values calculated for
our 1 model and average values calculated for the 176
structures are shown in Table 1. The occupancy rates of
both core and allowed regions for our 1 model are above
the average values calculated from the theoretical structures,
leading to a significant higher combined percentage in these
favorable regions (94.6 versus 91.6%). In contrast, the per-
centage of residues in two less favorable regions is much
lower for our model. By these comparisons, the quality of
our 1 structure appears to be acceptable when compared to
other theoretical models.
Figure 3 A shows a superposition of our 1 model with
the template protein CD11B(1ido). It is clear that the overall
topology of the template protein has been inherited while
some significant local configuration changes are presented
in variable regions. The Mg2 coordinating pattern remains,
although the sizes of the loops around the active site have
been altered. A detailed examination of residual type reveals
that the majority of charged residues are located on the
surface of our model whereas the core region is made of
mainly hydrophobic residues. This distribution, as portrayed
in Fig. 3 B, has been confirmed by a solvent-exposed sur-
face calculation in which the solvent exposed surface area
was compared to the total surface area for each residue type.
This led to an average ratio of 0.7 for all polar residues
and 0.3 for all hydrophobic residues. There are four
cysteine residues in 1 sequence that are not present in the
template, and they may contribute significantly to the over-
all topology of our 1 model. According to our sequence
alignment, one of them, C241, is located at the end of helix
a3 and in close proximity to C281 in a neighboring loop
between b7 and b8. Both of the remaining cysteines, C187
and C193, are in a single loop between b3 and b4 on the
other side of the molecule. Therefore, our 1 model may
have none, one, or two disulfide linkages. Generally speak-
ing, the cysteines in a protein have a strong tendency to
form disulfide linkages under favorable conditions, so we
have chosen to adopt the disulfide bond between C241 and
C281. Forming a disulfide linkage between C187 and C193
in the same loop, however, would result in a kink loop
configuration due to their sequential closeness. Further-
more, as shown in Fig. 2, we identified a highly homologous
protein fragment from methylamine dehydrogenase (PDB
entry 1mda) in which the two cysteines in the fragment
corresponding to the loop do not form a disulfide bond.
Therefore, we chose not to make the disulfide linkage
between C187 and C193, and instead model the loop from
the local template.
Due to its biological importance, the 1 subunit has
attracted an increasing number of experimental investiga-
tions aimed at elucidating the mechanism of ligand binding
(Tuckwell et al., 1994; Chen et al., 1998; Puzon-McLaugh-
lin and Takada, 1996). A number of critical residues in
ligand binding were identified by site-directed mutagenesis
technique. In addition to D130, which had previously been
shown important for ligand binding, Puzon-McLaughlin
also pin-pointed other residues, namely S132, N224, D226,
E229, D233, D267, and D295, that might also be critical to
ligand binding (Puzon-McLaughlin and Takada, 1996). It is
interesting that, together with D130, S134 and T206, S132
and D226 were also aligned in our model to the correspond-
ing MIDAS domain residues of the template proteins. As
pointed out earlier, the conserved DXSXS sequence is be-
lieved to be involved in the metal ion coordination and
integrin binding. Due to a high homology between the
model and template sequences in this region, it is likely that
these five residues of 1 are placed in topologically similar
positions to that of metal coordinating residues in the tem-
plate. Furthermore, due to residues N224 and E229 being
located in the same loop region between b5 and a3 in our
model and spatially close to metal coordinating residues
(Fig. 3 C), they should also contribute directly to ligand
binding. The other three residues, D233, D267, and D295,
are located in the separated regions on the molecule surface
(Fig. 3 C) and their involvement in ligand binding is not
well explained by our stand-alone 1 model. Because all of
them are located in the loop regions distant from the active
site, the mutations performed on them may induce adverse
effects on / association on immunoprecipitation under
TABLE 1 Comparison of 1 with theoretical structures from
the PDB
Value Calculated
Average
1 Structures (%)*
Average
Theoretical (%)*
Core 75.8 75.2
Allowed 18.8 16.4
Generously allowed 3.6 2.3
Disallowed 1.8 6.2
The ,  region percentages were calculated with PROCHECK V3.0. Only
176 out of the available 192 theoretical structures from PDB gave results
with PROCHECK.
*Percentages were averaged from raw data values and were normalized to
total 100%.
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the experimental condition, as speculated by Puzon-
McLaughlin and Takada (1996). Furthermore, their func-
tional roles in ligand binding may become clear upon the
association of 1 with 4 subunit (also see the VCAM
binding analysis in the next section).
To observe the conformational flexibility of our 1
model, we conducted a limited trajectory analysis on an
ensemble of minimized structures abstracted from a dy-
namic simulation. The molecular dynamics was carried out
under room temperature without any restraints for 200 ps.
FIGURE 3 Color ribbon/trace representation of 1 model. (A) Comparison of refined 1 model in magenta with its template protein CD11B(1ido) in
orange. Those residues involved in metal-ion coordination are highlighted. (B) Color-coded residue distribution of 1 model. Green, mostly hydrophobic
residues (A, V, F, L, I); yellow, charged hydrophilic residues (D, E, K, R, H); purple, remaining. (C) Distribution of critical residues identified by the site
directed mutagenesis data. Residues in blue are those believed to associate with metal-ion coordination, whereas those in yellow are speculated to contribute
to  association. (D) Superposition of 1 conformations extracted from a dynamics simulation. An ensemble of C traces in different colors represent
snap shots of 1 conformations from a dynamic trajectory.
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Figure 3 D shows the superposition of an ensemble of
minimized 1 conformations abstracted from the dynamic
trajectory. The standard deviation data suggest that the
configurations of SCRs are rather preserved, whereas the
loop regions on both top and bottom of the model demon-
strate a certain degree of conformational mobility. This is in
line with our expectation, because the SCRs mainly form
the structure core of our 1 model and, therefore, are
spatially more constrained.
Ligand binding analysis
The refined 1 model was used to study its ligand-binding
mechanism. The first molecule used is an active cyclic
peptide TBC772 derived from a section within the CS-1
splice variant of fibronectin (McIntyre et al., 1997). Cy-
clization of this short peptide greatly reduced the backbone
conformational flexibility. Figure 4 A shows the detailed
binding interactions between TBC772 and active site resi-
dues in our 1 model. The carboxylic acid of Aspartic acid
in TBC772 lies above the Mg2 ion in its coordination
sphere. This coordination is supported by the crystal struc-
ture of CD11B, which shows the sixth coordination site
occupied by residue E314 from a neighboring CD11B mol-
ecule (Lee et al., 1995a,b). The Val and Leu in TBC772
share favorable hydrophobic interactions with L205 and
P228 of the 1 model, respectively. Furthermore, the NH of
the indole ring in tryptophan can form a hydrogen bond with
E229 in our 1 model. This interaction might partially
account for the role of E229 in ligand binding. Given the
intrinsic flexibility of a homology model, one might argue
that L205 and P228, located in two different loops around
an active site, are, by chance, placed near the active site
during our model building. However, this possibility can be
eliminated if we examine their sequential relationship with
the key residues for metal ion coordination. For example,
L205 is next to T206 and P228 is sandwiched between
D226 and E229. Therefore, the locations of these two res-
idues are rather restrained in the active site due to the
conserved MIDAS motif geometry. Furthermore, both L205
and P228 are evolutionarily conserved throughout all 
subunits, implicating possible biological functions. From
the above discussion, it is clear that each of four peptide
residues in TBC772 has found its favorable partner in the
active site, and these interactions should have contributed to
the high binding affinity of TBC772 for 1.
With the success of docking TBC772 to our 1 model,
we extended the ligand binding study to include some active
nonpeptide compounds. One of these compounds,
TBC3486, is a VLA-4 antagonist with an IC50 of 0.4 nM in
the CS-1 assay. Figure 4 B presents a possible binding mode
of TBC3486 to our 1 model. This binding mode was
achieved by superimposing its carboxylic acid with that of
docked TBC772 while maximizing the contact between its
two hydrophobic groups with L205 and P228 of 1. Ac-
cording to this binding mode, S227 and K208 in 1 are
hydrogen bonded, respectively, to the urea NH groups and
the nonurea carbonyl oxygen of TBC3486, two critical
pharmacophore features determined from our active analog
analysis (Holland, 1999). Also, Y133 is hydrogen bonded to
one of the oxygens in the methylenedioxy fragment of
TBC3486. Residues Y133 and S227 are another pair of
interesting active site residues, because, with a hydroxyl
group, they can act as either a hydrogen-bond donor or
acceptor, facilitating their hydrogen-bonding capacity with
ligands. For instance, in addition to its hydrogen bond to the
urea NH groups in TBC3486, S227 can also form a hydro-
gen bond with the carboxylic acid group of E229 and
stabilize the configuration of the loop. In contrast, residue
Y133 may also contribute to hydrophobic interaction be-
tween ligand and receptor by ring stacking. Arguments for
this type of interaction are supported by the results of a
binding assay in which there was no apparent loss in activity
after replacing methylenedioxyl in TBC3486 with a substi-
tuted aromatic ring (unpublished data). Like L205 and
P228, the positions of Y133, K208, and S227 in the active
site are rather limited because they are also neighbored by
the key metal ion-coordinating residues. However, these
three residues are not evolutionarily conserved throughout 
subunits, and their participation in ligand binding might
lead to binding selectivity among different  subunits.
The binding analysis of small synthetic compounds pre-
sented above provides us rich information about the mech-
anism by which 1 interacts with its ligands. This in turn
facilitates our ability to understand how 41 complex
interacts with its native ligand VCAM. It has been shown
that residues QIDSPY in domain I of VCAM are critical in
its binding to 41 and, by symmetry, a highly charged
loop in domain II is also speculated to be important in
binding (Newham et al., 1997; Green et al., 1999). It is
interesting that IDSP loop shares sequence similarity with
TBC772, which was derived from CS-1. This suggests that
it might bind to 1 in a similar fashion to TBC772. Docking
of this loop into 1 active site by aligning the carboxylic
acid of Asp to the same group in docked TBC772 (see Fig.
4 C) leads us to the orientation shown in Fig. 4 D. It is
interesting that this docking orientation retains most of
favorable interactions between the ligand and receptor while
avoiding steric clashes between the domains of two mole-
cules. Again, L205 and P228 share close hydrophobic in-
teractions with proline and isoleucine in the VCAM loop,
respectively, and the OH group of serine in the loop is
within the hydrogen bonding range of both N207 and E229
of 1 model. An interesting observation of this docking
orientation is that it places the other domain of VCAM in
such a position that its highly charged loop is in the neigh-
borhood of 1 residues D233, D267, and D295. One side of
this loop, LEDADRKSL, is arrayed by positively charged
residues with hydrogen-bond donor potential, whereas an-
other side is made of negatively charged hydrogen-bond
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acceptor residues. Docking of VCAM domain I loop orients
the positively charged portion of the loop toward key 1
residues D233 and D267 and places the negatively charged
section exposed to the space that would possibly be occu-
pied by the  subunit. This would suggest that the binding
site of 4 subunit should be either metal-ion coordinated or
FIGURE 4 Ligand-binding analysis based on the refined 1 model. Ligands are colored by their atom types: O red; N blue; C green; S yellow.
1 residues proposed as critical for ligand binding are indicated by orange, whereas those in blue denote metal-coordinating residues. (A) Docking of
TBC772 to 1 model. A 2D sketch of TBC772 structure is also included. (B) Docking of TBC3486 to 1 model. A 2D sketch of TBC3486 is also attached.
(C) Docking of the IDSP loop in VCAM domain I to 1. (D) Docking of VCAM domain 1 to 1 model leads to a specific orientation of the LEDADRKSL
loop in VCAM domain II to 1 model. VCAM is colored light blue and three critical binding residues in 1, D233, D267, and D295, are colored yellow.
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in a highly positively charged state. This is consistent with
a model of the  subunit in which a Mg ion is predicted to
bind to its upper face (Springer, 1997). With the proposed
involvement of residues Y133, L205, K208, S227, and P228
to the binding of TBC772/TBC3486 type ligands to 1
subunit, it is useful to compare their distribution in the
active site to a previously derived pharmacophore model
(Holland, 1999). In Fig. 5, the geometric relationship be-
tween the key binding residues in our 1 model is compared
to the pharmacophore model. It is important to understand
that the pharmacophore, which specifies the geometric re-
lationship between the key functional groups in active com-
pounds, should be complementary to the characteristics of
critical residues in the active site. Obviously, L205 and
P228 can fill two hydrophobic regions specified by the
pharmacophore model rather well. Residues Y133, K208,
and S227 can each map to one of the hydrogen bonding
features in the pharmacophore model, namely Y133 to HA
or aromatic, K208 to HD, and S227 to HA. In matching both
the features and the geometry specified by the pharmacoph-
ore model, our 1 model provides us with a receptor struc-
ture-based explanation on why the functional elements of
the pharmacophore model are important to ligand binding.
1/7 Binding selectivity
Selectivity between 41 and 47 is important because
the diseases attenuated by inhibition of these homologous
integrins are different in many cases (Green et al., 1999).
Our activity assay results for TBC3486 show a 1000-fold
selectivity in favor of 41 (unpublished data). Because the
sequence homology is extremely high for these two 
subunits (61% identity and 78% similarity) they should
share closely resembled structural and topological features
(see Fig. 6 A). It is reasonable to assume that the binding
selectivity between these two subunits arises from the mu-
tations of some critical residues, especially those in the
active site. However, the sequence alignment indicates that
most key residues for metal-ion coordinating and ligand
binding, including those suggested by mutagenesis experi-
ments and those proposed by our model, are totally con-
served between 1 and 7. Therefore, those residues seem
unlikely to account for binding selectivity. In search of the
residues that might be responsible for the selectivity, we
investigated all residues within 12 Å of the Mg ion in our 1
model, which effectively covers the entire 1 active site. All
residues in this region except five are conserved between 1
and 7. Out of these five, only Asn/Gly-207 and Lys/Asp-
208 may cause significant physiochemical disturbance to
their local area. A detailed examination of the structural
environment of these two residues in our 1 model has
revealed the structural roles these mutations might play in
the ligand binding selectivity. According to our 1 model,
N207 and K208 are located in the loop between b4 and a2
next to the metal ion coordinating residue T206. As shown
in Fig. 6 B, the positively charged K208 has found itself a
comfortable electrostatic environment in which it is sur-
rounded by the E229 side chain and the backbone carbonyls
of S227 and P228. Residue N207 also forms a hydrogen
bond with the carboxylic acid group of E229. As discussed
earlier, E229 was identified by mutagenesis experiments as
critical for 1 ligand binding and it is sequentially next to
residues D226–P228, and together they form a loop be-
tween b5 and a3. The favorable electrostatic interaction
between N207K208 and E229 should play an important role
in achieving and maintaining the relative orientation be-
tween these two loops in our 1 model. The Asn/Gly-207
and Lys/Asp-208 changes not only cause the loss of the
hydrogen bond between N207 and E229, but also introduce
a large electrostatic repelling force between D208 and E229.
These two modifications cause a reorientation between the
two loops. Since both loops contain a number of critical
residues in metal coordination and ligand binding their
reorientation will inevitably alter the geometric distribution
of these residues and this is presumably the cause of ligand
selectivity between 1 and 7. To lend support to this
argument, we have conducted a limited loop conformational
search on a modified 1 model in which N207 and K208
were replaced by G207 and D208, respectively. The search
was carried out through a restrained dynamics simulation in
which all residues other than those in the active site were
fixed. The conformations sampled from the dynamics tra-
jectory were then refined by a minimization protocol. In
Fig. 6 C, the active site loops in our original 1 model are
FIGURE 5 Comparison of the pharmacophore features derived from
active analog analysis to 1 active site residue distribution. Active site
residues proposed to be critical for binding are colored by their atom types,
and the metal ion Mg2 is represented by a gray sphere. Each pharma-
cophore feature is also represented by a sphere of different colors: Orange,
acid; purple, hydrogen bond acceptor (HA); blue, hydrogen bond donor
(HD); and green, hydrophobic group.
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compared to those in derived 7 model with special high-
light to the positions of K208D and E229. It is clear that
D208 and E229 have moved significantly from their origi-
nal positions in 1 to compensate the unfavorable electro-
static interaction between them. The reposition of these two
side chains causes loops in the active site to reorient, which
in turn alters the positions of many critical binding residues.
Though it is beyond the scope of this paper, a quantitative
description of change in binding affinity, such as those
provided by a free energy calculation, should provided more
convincing support. Nevertheless, the analysis presented
here provides a qualitative explanation for binding selectiv-
ity between 1 and 7 subunits.
CONCLUSIONS
Based on the template of I domain from integrin  subunit
CD11A/CD11B, we have built a 3D structural model for 1
subunit and used the model to study the possible binding
mechanism of 1 with VCAM and other highly active
ligands. The sequence alignment based on the mapping of
secondary structure motifs ensured the preservation of
structurally conserved regions from the template. The re-
fined 1 structure is comparable in quality to other theoret-
ical models and the model has a reasonable residual distri-
bution in which most hydrophilic residues are located on the
molecular surface. Furthermore, the model can satisfactorily
explain most mutagenesis data available. Based on the li-
gand docking analysis, the model active site fits our previ-
ously derived pharmacophore specification (Holland, 1999)
very well, and a number of residues that might also con-
tribute significantly to ligand binding have been identified.
The model has also been used to propose the possible
mechanism behind 1/7 ligand binding selectivity. In
summary, the model provides valuable structure informa-
tion about the ligand binding to the 1 subunit and
41complex, which in turn benefits the search for poten-
tial therapeutic agents.
FIGURE 6 Proposed mechanism of ligand binding selectivity between 1 and 7. (A) Sequence alignment between 1 and 7. (B) The local environment
of residue K208 in 1 model. Critical residues are colored by their atom types. (C) The simulated local conformational changes caused by Asn/Gly-207
and Lys/Asp-208 from 1 to 7. Original 1 model is colored purple, and modified 1 model is colored blue.
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